&bgr;-blockers and their mortality benefits: underprescribed in heart failure and chronic obstructive pulmonary disease

ISSN： 1479-6678

Source： Future Cardiology, Vol.7, Iss.1, 2011-01, pp. : 43-53

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Heart failure, chronic obstructive pulmonary disease, and asthma: numbers, facts, and challenges

ESC HEART FAILURE, Vol. 2, Iss. 3, 2015-09 ,pp. : 103-107

John Wiley & Sons Inc

Access to resources Recommend Favorite

Chronic Obstructive Pulmonary Disease

Medical Principles and Practice, Vol. 7, Iss. 1, 1998-04 ,pp. : 1-17

Karger

Access to resources Recommend Favorite

Asthma, Chronic Obstructive Pulmonary Disease, and Mortality in the U.S. Population

By Diaz-Guzman Enrique Khosravi Mehdi Mannino David M.

COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 8, Iss. 6, 2011-12 ,pp. : 400-407

Informa Healthcare

Access to resources Recommend Favorite

Mortality after an Emergency Department Visit for Exacerbation of Chronic Obstructive Pulmonary Disease

By Kim Sunghye Clark Sunday Camargo Carlos

COPD: Journal of Chronic Obstructive Pulmonary Disease, Vol. 3, Iss. 2, 2006-07 ,pp. : 75-81

Informa Healthcare

Access to resources Recommend Favorite

The role of systemic inflammatory biomarkers to predict mortality in chronic obstructive pulmonary disease

By Kelly Emer Owen Caroline A Pinto-Plata Victor Celli Bartolome R

Expert Review of Respiratory Medicine, Vol. 7, Iss. 1, 2013-02 ,pp. : 57-64

Informa Healthcare

Access to resources Recommend Favorite